Finerenone Shows Consistent Cardiovascular and Kidney Benefit Across CKM Syndrome Stages in Type 2 Diabetes and CKD

Article Structure

This article is organized to mirror how clinicians typically appraise practice-relevant trial analyses: clinical background and unmet need; study design and analytic framework; detailed efficacy and safety findings; interpretation in the context of CKM syndrome biology, prior finerenone evidence, and guideline relevance; limitations and generalizability; and a concise clinical bottom line.

Highlights

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply